ECM
APLS

Endurant Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Endurant Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-19,362
Closed -$593K – 55
2019
Q4 		$593K Sell
19,362
-2,919
-13% -$80.8K 0.19% 45
2019
Q3 		$537K Buy
+22,281
New +$613K 0.19% 47
2018
Q1 		– Sell
-17,600
Closed -$382K – 70
2017
Q4 		$382K Buy
+17,600
New +$259K 0.12% 72

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Endurant Capital Management's APLS Position: Q1 2020 in Review

Endurant Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2020, closing a stake of 19,362 shares — an estimated $593K sold.

Endurant Capital Management first reported a position in APLS in Q4 2017 and held it in 3 quarters. The position peaked at $593K in Q4 2019. 143 funds tracked by Wall St. Rank hold APLS as of Q1 2020.

  • Endurant Capital Management reported no remaining Apellis Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Endurant Capital Management sold 19,362 Apellis Pharmaceuticals shares in Q1 2020, an estimated $593K.
  • Endurant Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Endurant Capital Management's Apellis Pharmaceuticals position peaked at $593K in Q4 2019.
  • 143 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2020.

Based on Endurant Capital Management's 13F filing for Q1 2020, filed 15 May 2020.